Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045825873> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2045825873 endingPage "8" @default.
- W2045825873 startingPage "3" @default.
- W2045825873 abstract "To investigate effectiveness of long-term treatment of myasthenia gravis (MG) with intravenous immunoglobulin (IVIG).There are no definitive studies showing effectiveness of IVIG therapy in long-term treatment of MG. Most studies have investigated the acute treatment of MG with IVIG. We describe our experience with long-term treatment of MG with IVIG in six patients.Acute treatment of MG by IVIG therapy has been well established in the literature. We describe six patients who were treated on a long-term basis with IVIG therapy. All of these patients had positive acetylcholine receptor antibody titers. They all received initial infusion for 5 days of IVIG at a dose of 400 mg/kg/day followed by maintenance therapy of 400 mg/kg for 1 day every 3-4 months. These patients were followed for 2 years. All other medications, including prednisone and cholingeric drugs such as Mestinon, were gradually weaned. For the last years, each of these patients maintained better than functional class 2 on an average of 1.5-2.2+/-0.5 grades on the University of Virginia modification of Ossermann's classification scale for MG. They were solely treated with IVIG infusion every 3-4 months without any other concomitant medications. Three of the patients had previously undergone thymectomies. None of the patients noticed any worsening in their scores on the University of Virginia modification of Ossermann's classification worse than Grade II in the last 2 years. There were no complications related to IVIG therapy, and all patients tolerated a single infusion of IVIG every 3-4 months at 400 mg/kg for 1 day.Our study demonstrates that IVIG maintenance is effective treatment of MG in selected patients and it is well tolerated.IVIG therapy is a convenient, effective therapy when used selectively for treatment of MG on a long-term basis without any significant side effects." @default.
- W2045825873 created "2016-06-24" @default.
- W2045825873 creator A5004294902 @default.
- W2045825873 creator A5072435769 @default.
- W2045825873 date "2002-12-01" @default.
- W2045825873 modified "2023-10-06" @default.
- W2045825873 title "Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis" @default.
- W2045825873 cites W1975133991 @default.
- W2045825873 cites W1977282646 @default.
- W2045825873 cites W1979988008 @default.
- W2045825873 cites W1993520265 @default.
- W2045825873 cites W1993694158 @default.
- W2045825873 cites W1997137774 @default.
- W2045825873 cites W2001447887 @default.
- W2045825873 cites W2019791196 @default.
- W2045825873 cites W2032967230 @default.
- W2045825873 cites W2036781293 @default.
- W2045825873 cites W2052934267 @default.
- W2045825873 cites W2054456664 @default.
- W2045825873 cites W2064436710 @default.
- W2045825873 cites W2078425070 @default.
- W2045825873 cites W2089502456 @default.
- W2045825873 cites W2113436149 @default.
- W2045825873 cites W2168664900 @default.
- W2045825873 doi "https://doi.org/10.1016/s0303-8467(02)00017-3" @default.
- W2045825873 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12445915" @default.
- W2045825873 hasPublicationYear "2002" @default.
- W2045825873 type Work @default.
- W2045825873 sameAs 2045825873 @default.
- W2045825873 citedByCount "28" @default.
- W2045825873 countsByYear W20458258732012 @default.
- W2045825873 countsByYear W20458258732013 @default.
- W2045825873 countsByYear W20458258732014 @default.
- W2045825873 countsByYear W20458258732016 @default.
- W2045825873 countsByYear W20458258732017 @default.
- W2045825873 countsByYear W20458258732020 @default.
- W2045825873 countsByYear W20458258732021 @default.
- W2045825873 countsByYear W20458258732022 @default.
- W2045825873 crossrefType "journal-article" @default.
- W2045825873 hasAuthorship W2045825873A5004294902 @default.
- W2045825873 hasAuthorship W2045825873A5072435769 @default.
- W2045825873 hasBestOaLocation W20458258731 @default.
- W2045825873 hasConcept C126322002 @default.
- W2045825873 hasConcept C141071460 @default.
- W2045825873 hasConcept C159654299 @default.
- W2045825873 hasConcept C203014093 @default.
- W2045825873 hasConcept C2778105408 @default.
- W2045825873 hasConcept C2778720950 @default.
- W2045825873 hasConcept C2779384505 @default.
- W2045825873 hasConcept C71924100 @default.
- W2045825873 hasConceptScore W2045825873C126322002 @default.
- W2045825873 hasConceptScore W2045825873C141071460 @default.
- W2045825873 hasConceptScore W2045825873C159654299 @default.
- W2045825873 hasConceptScore W2045825873C203014093 @default.
- W2045825873 hasConceptScore W2045825873C2778105408 @default.
- W2045825873 hasConceptScore W2045825873C2778720950 @default.
- W2045825873 hasConceptScore W2045825873C2779384505 @default.
- W2045825873 hasConceptScore W2045825873C71924100 @default.
- W2045825873 hasIssue "1" @default.
- W2045825873 hasLocation W20458258731 @default.
- W2045825873 hasLocation W20458258732 @default.
- W2045825873 hasOpenAccess W2045825873 @default.
- W2045825873 hasPrimaryLocation W20458258731 @default.
- W2045825873 hasRelatedWork W1985127333 @default.
- W2045825873 hasRelatedWork W2005139163 @default.
- W2045825873 hasRelatedWork W2091716289 @default.
- W2045825873 hasRelatedWork W2370818147 @default.
- W2045825873 hasRelatedWork W2418216271 @default.
- W2045825873 hasRelatedWork W2433746147 @default.
- W2045825873 hasRelatedWork W2921987722 @default.
- W2045825873 hasRelatedWork W3031767843 @default.
- W2045825873 hasRelatedWork W4237377959 @default.
- W2045825873 hasRelatedWork W596128687 @default.
- W2045825873 hasVolume "105" @default.
- W2045825873 isParatext "false" @default.
- W2045825873 isRetracted "false" @default.
- W2045825873 magId "2045825873" @default.
- W2045825873 workType "article" @default.